REDWOOD CITY, Cailf., Oct. 28 /PRNewswire-FirstCall/ -- Codexis, Inc. (Nasdaq: CDXS) today announced financial results for the third quarter ended September 30, 2010.
Revenue: For the third quarter of 2010, the company reported revenues of $27.1 million, an increase of 35% from $20.1 million in the third quarter of 2009, primarily due to an increase of $4.9 million in product revenue, representing an increase of 105% over the same time period.
Operating Expenses: Research and development expenses in the third quarter of 2010 were $13.1 million, compared to $12.2 million for the third quarter of 2009. The increase was primarily due to higher depreciation and stock-based compensation expenses. Selling, general and administrative expenses in the third quarter of 2010 declined to $7.9 million compared to $8.7 million same period of 2009 primarily due to a reduction in discretionary expenses.
Net Income/(Loss): Net loss was ($2.7) million, or ($0.08) per share, based on 34.2 million weighted average common shares outstanding in the third quarter of 2010. This compares to a net loss of ($6.2) million during the third quarter of 2009.
Adjusted EBITDA: On a non-GAAP basis, Adjusted EBITDA increased from ($2.7) million in the third quarter of 2009 to $2.1 million in 2010. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation. A reconciliation of net loss to Adjusted EBITDA is presented below.
Cash: Cash, cash equivalents and marketable securities at September 30, 2010 decreased to $99.3 million compared to $100.3 million at June 30, 2010.
Codexis' statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.
Codexis increases its full year revenue guidance for 2010. For full year 2010, Codexis forecasts revenues of greater than $100 million, which would represent growth of 21% or greater compared to 2009. Codexis affirms its expectation that Adjusted EBITDA will be positive for the full year 2010; and expects Adjusted EBITDA will be greater than $7 million for the year.
Codexis will hold a conference call for investors on October 28, 2010 at 1:30 p.m. PT (4:30 p.m. ET). The conference call dial-in numbers are US: 866-788-0541 or International: 857-350-1679, access code 54501345. A live webcast of the call will also be available from the Investor Relations section of www.codexis.com. A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 43072209 beginning approximately two hours after the call, and will be available for up to thirty days. A webcast replay from today's call will also be available from the Investor Relations section of www.codexis.com approximately two hours after the call and will be available for up to thirty days.
About Codexis, Inc.
Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets for the company's biocatalyst-enabled solutions include carbon capture, water treatment and chemicals.
This press release contains forward-looking statements relating to the company's forecast for 2010 revenue and Adjusted EBITDA, which is defined elsewhere in this press release. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2010, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
Three Months Ended
Nine Months Ended
Related party collaborative research and development
Collaborative research and development
Costs and operating expenses:
Cost of product revenues
Gross margin $
Gross margin %
Research and development
Selling, general and administrative
Total costs and operating expenses
Loss from operations
Interest expense and other, net
Loss before provision (benefit) for income taxes
Provision (benefit) for income taxes
Net loss per share of common stock,
basic and diluted
Weighted average common shares used in computing net loss per share of common stock, basic and diluted
Condensed Consolidated Balance Sheets
Cash and cash equivalents
Accounts receivable, net
Related party accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Intangible assets, net
Other non-current assets
Liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit)
Related party payable
Other accrued liabilities
Redeemable convertible preferred stock warrant liability
Related party deferred revenues
Total current liabilities
Deferred revenues, net of current portion
Related party deferred revenues, net of current portion
Financing obligations, net of current portion
Other long-term liabilities
Redeemable convertible preferred stock issuable in series A to F
Stockholders' equity (deficit):
Additional paid-in capital
Accumulated other comprehensive loss
Total stockholders' equity (deficit)
Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit)
Condensed Consolidated Statements of Cash Flow
Nine Months Ended
Adjustments to reconcile net loss to cash used in
Amortization of intangible assets
Depreciation and amortization of property and equipment
Revaluation of redeemable convertible preferred stock warrant liability
Gain on disposal of property and equipment
Amortization of debt discount
Accretion (amortization) of premium/discount on marketable securities
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accrued related party payable
Other accrued liabilities
Net cash (used in) operating activities
Decrease in restricted cash
Purchase of property and equipment
Purchase of of marketable securities
Proceeds from sales of marketable securities
Proceeds from maturities of marketable securities
Net cash provided by (used in) investing activities
Principal payments on financing obligations
Payments in preparation for initial public offering
Proceeds from issuance of preferred stock
Proceeds from issuance of common stock on IPO, net of underwriting discounts
Proceeds from exercises of stock options
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents:
Beginning of the period
End of the period
Marketable securities at the end of period
Cash, cash equivalents and marketable securities
Reconciliation of GAAP to Non-GAAP Financial Information
Adjusted EBITDA (calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation ) for the third quarter of 2010 was $2.1 million compared to a loss of $2.7 million in the third quarter of 2009. For the nine months ended September 30, 2010, Adjusted EBITDA improved to $5.5 million from a loss of $6.2 million in the same period in 2009. The key driver of this improvement was a $7.1 million reduction in net loss.
In this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA as a factor in evaluating management's performance when determining incentive compensation and to evaluate the effectiveness of our business strategies.
A reconciliation of GAAP net income (loss) to Adjusted EBITDA is included in the table below.
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
Three months ended
Nine months ended
Net income (loss)
Minus: Interest income
Plus: Interest expense
Plus: Income taxes
Plus: Depreciation and amortization
Plus: Stock-based compensation
Plus: Preferred stock warrant fair market valuation adjustment
Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:
- Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
- Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
- Adjusted EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debts;
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
- Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.
Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.
SOURCE Codexis, Inc.